Brit Mollenhauer, MD, is a physician-scientist and Professor at the University Medical Center Göttingen (UMG). She is head of Translational Science at the Movement Disorders Center of the Paracelsus-Elena-Klinik, Kassel, Germany. She completed neurology training at UMG and a postdoctoral fellowship at Harvard Medical School, Boston. She has developed a translational research program focusing on biomarker development for early and prodromal diagnosis, for the progression of Parkinson’s disease (PD), and related deep phenotyping. Dr. Mollenhauer has launched several observational cohorts, including the De Novo PD (DeNoPa) cohort based in Kassel to better understand the natural history of PD and variants of manifest disease as well as their prodromal stages. Her interdisciplinary research program spans the pathophysiology, epidemiology, and deep phenotyping of PD. Dr. Mollenhauer has received several awards and also serves on the Executive Scientific Advisory Board of the Parkinson’s Progression Markers Initiative from the Michael J. Fox Foundation.
Co-PI (Core Leadership)
Brit Mollenhauer, MD
University of Goettingen
Brit Mollenhauer, MD, is a physician-scientist and Professor at the University Medical Center Göttingen (UMG). She is head of Translational Science at the Movement Disorders Center of the Paracelsus-Elena-Klinik, Kassel, Germany. She completed neurology training at UMG and a postdoctoral fellowship at Harvard Medical School, Boston. She has developed a translational research program focusing on biomarker development for early and prodromal diagnosis, for the progression of Parkinson’s disease (PD), and related deep phenotyping. Dr. Mollenhauer has launched several observational cohorts, including the De Novo PD (DeNoPa) cohort based in Kassel to better understand the natural history of PD and variants of manifest disease as well as their prodromal stages. Her interdisciplinary research program spans the pathophysiology, epidemiology, and deep phenotyping of PD. Dr. Mollenhauer has received several awards and also serves on the Executive Scientific Advisory Board of the Parkinson’s Progression Markers Initiative from the Michael J. Fox Foundation.
